NSE seeks clarification on Q1 results under SEBI Regulation 33

SUPRIYA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.8%Reaction day

₹803.50

prior close

₹842.35

announcement price

In-mkt

timing

Nifty Microcap 250market-0.6%+5.4% vs market

Pharmaceuticals peers, median of 171sector-0.2%+5.0% vs sector

On the reaction day the stock moved 5.4 pts more than Nifty Microcap 250 and 5.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

+0.2

15m

+0.1

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.8-0.6+5.4-0.2+5.0

Next day

+5.0+0.0+5.0+0.2+4.7

+5.3+0.7+4.6+0.1+5.1

+13.6+1.1+12.5+0.6+13.1

+14.0+1.6+12.4+0.8+13.2

+13.1+1.5+11.6+0.0+13.1

+12.6+1.4+11.2+0.5+12.1

15d

+19.7+0.4+19.3+0.7+19.0

+12.3-1.4+13.7-2.1+14.4

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

NSE has asked Supriya Lifescience to clarify certain points related to its financial results for the quarter ended 30-Jun-2026 under SEBI's Listing Obligations and Disclosure Requirements Regulation 33. The company has not yet responded. This is a routine exchange query, not an enforcement action.

Likely market impact

Usually routine, but watch for company's response; could affect sentiment if clarification is delayed.